department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Yonsa · pharmadog

pharmadog
drugs
Yonsa

drug

patient view →

Yonsa

Marketedupdated 2mo ago

by Sun Pharmaceutical Industries Ltd

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 9 investigational indications.

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Yonsa

generic

abiraterone acetate

MOA

Cytochrome P450 17A1 inhibitor

indication

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 17, 2034

~7.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (2)

May 20, 2034method-of-use (U-2535)US 10292990
Mar 17, 2034formulationUS 9889144

Data sources

ClinicalTrials.gov

last refreshed 23m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 6

drugAKEEGA4 co-mentions · 2 sources
tagApproval4 co-mentions · 2 sources
drug(abiraterone acetate + niraparib)2 co-mentions · 2 sources
drugabiraterone acetate2 co-mentions · 2 sources
companyJanssen Biotech Inc2 co-mentions · 2 sources
tagSmall Molecule2 co-mentions · 2 sources

Trials studying Yonsa

phase1A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Canceractive not recruitingn=136
phase1A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Canceractive not recruitingn=57
phase1M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)active not recruitingn=60
phase3A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancerrecruitingn=750
phase2Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.recruitingn=192
phase2A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancerrecruitingn=100
phase3A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)recruitingn=1,314
phase2A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Canceractive not recruitingn=136

more trials →